NUDGE-EHR Replication Trial at Mass General Brigham (NUDGE-EHR)
Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction
About this trial
This is an interventional health services research trial for Aging focused on measuring Benzodiazepine, Sedative hypnotic, Overprescribing, Anticholinergic
Eligibility Criteria
Inclusion Criteria:
- Primary care provider at Mass General Brigham
Providers will receive these EHR tools for their patients who meet the following criteria:
- older adults (aged 65 years or more)
- who have been prescribed at least 90 pills of benzodiazepine or sedative hypnotic in the last 180 days.
Outcomes will be measured on the patient level.
Exclusion Criteria:
- N/A
Sites / Locations
- Mass General BrighamRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Experimental
No Alert (Usual Care)
Open Encounter + Pre-commitment
Open Encounter + Follow-up booster
Providers randomized to usual care will receive no intervention.
There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.